VK2735 Research# VK2735's evidence base consists of phase 2 trials: VENTURE (subcutaneous): 176 adults with obesity, 13 weeks, up to 14.7% weight loss from baseline (placebo-adjusted 13.1%) VENTURE-Oral: Oral tablet formulation, 13 weeks, up to 12.2% weight loss vs 1.3% placebo Phase 3 VANQUISH program: Planned but not yet initiated at time of writing Evidence level: Low -- promising phase 2 data only, short duration, small sample sizes, no head-to-head comparisons
doi:10.1093/jn/130.4.1007s
doi: 10.1053/j.gastro.2017.01.052 22
The Latiar became an important feature of Roman political life as they were feriae conceptivae , i
2000;130(4S Suppl):1058S-62S
Because RP is a chronic condition, the development of a minimally invasive therapeutic that reduces frequency of application with local administration is appealing to reduce risk of non-adherence